Potential of St John's Wort for the treatment of depression: the economic perspective

References

• National Advisory Council on Mental Health. A mentally healthy future for all Australians. Canberra: National Advisory Council on Mental Health, 2009.
   Google Scholar
• Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349:1498–1504.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005; 62:593–602.
   PubMed Web of Science ®Google Scholar
• Welfare AIoHa. Australia's Health 2008. Canberra: Australian Institute of Health and Welfare, 2008.
   Google Scholar
• Ernst E, Rand J, Stevinson C. Complementary therapies for depression. Arch Gen Psychiatry 1998; 55:1026–1032.
   PubMed Web of Science ®Google Scholar
• Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to informpublic policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 2004; 184:526–533.
   PubMed Web of Science ®Google Scholar
• Kendrick T, Chatwin J, Dowrick C. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technology Assessment 2009; 13:1–198.
   Web of Science ®Google Scholar
• Bosmans J, Hermens M, de Bruijne M . Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. J Affect Disord 2007; 111:106–112.
   Web of Science ®Google Scholar
• Hollinghurst S, Shaw A, Thompson EA. Capturing the value of complementary and alternative medicine: including patient preferences in economic evaluation. Complement Ther Med 2008; 16:47–51.
   PubMed Web of Science ®Google Scholar
• Herman P, Craig B, Caspi C. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complement Altern Med 2005; 5.
   PubMedGoogle Scholar
• Baker C, Woods S. Cost of treatment failure for major depression: direct costs of continued treatment. Adm Policy Ment Health 2001; 28:263–277.
   PubMed Web of Science ®Google Scholar
• Crown W, Finkelstein S, Berndt E . The impact of treatment-resistant depression on healthcare utilization and costs. J Clin Psychiatry 2002; 63:963–971.
   PubMed Web of Science ®Google Scholar
• Sullivan P, Valuck R, Saseen J, MacFall H. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911–932.
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Davis R, Ettner S . Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280:1569–1575.
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Kessler R, Foster C, Norlock F, Calkins D, Delbanco T. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246–252.
   PubMed Web of Science ®Google Scholar
• Hsu M-C, Creedy D, Moyle W, Venturato L, Tsay S-L, Ouyang W-C. Use of complementary and alternative medicine among adult patients for depression in Taiwan. J Affect Disord 2008; 111:360–365.
   PubMed Web of Science ®Google Scholar
• Hsu M-C, Moyle W, Creedy D, Venturato L, Ouyang W-C, Tsay S-L. Use of antidepressants and complementary and alternative medicine among outpatients with depression in Taiwan. Arch Psychiatr Nurs 2009; 23:75–85.
   PubMed Web of Science ®Google Scholar
• Kessler R, Soukup J, Davis R . The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001; 158:289–294.
   PubMed Web of Science ®Google Scholar
• Knaudt P, Connor K, Weisler R, Churchill L, Davidson J. Alternative therapy use in psychiatric outpatients. Journal of Nervous and Mental Disease 1998; 187:692–695.
   Web of Science ®Google Scholar
• Wong A, Smith M, Boon H. Herbal remedies in psychiatric practice. Archives of General Psychiatry 1998; 55:1033–1045.
   PubMed Web of Science ®Google Scholar
• Knaudt P, Connor K, Weisler R, Churchill L, Erik M, Davidson J. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999; 187:692–695.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Crothers D. Who sees homeopaths? Br Homoeopath J 1991; 80:57–58.
   Google Scholar
• Jansen G, Koster T. Complaints and diagnoses in homeopathic practice. Br Homoeopath J 1995; 84:140–143.
   Google Scholar
• Gray C, Pronk N, O'Connor P. Complementary and alternative medicine use among health plan members: a cross-sectional survey. Eff Clin Pract 2002; 5:17–22.
   PubMedGoogle Scholar
• Kaufman D, Kelly J, Rosenberg I, Anderson T, Mitchell A. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone survey. JAMA 2002; 287:337–344.
   PubMed Web of Science ®Google Scholar
• Fournier J, DeRubeis R, Hollon S . Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303:47–53.
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon B, Huedo-Medina T, Scoboria A, Moore T, Johnson B. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5(2): e45.
   PubMed Web of Science ®Google Scholar
• Kendrick T, Peveler R, Longworth L, Baldwin D, Moore M, Chatwin J . Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. Br J Psychiatry 2006; 188:337–345.
   PubMed Web of Science ®Google Scholar
• Rapaport M, Judd L, Schettler P . A descriptive analysis of minor depression. Am J Psychiatry 2002; 159:637–643.
   PubMed Web of Science ®Google Scholar
• Lee S, Walker J, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 2004; 19:10–19.
   PubMed Web of Science ®Google Scholar
• Fisher P, Van Haselen R, Hardy K, Berkovitz S, McCarney R. Effectiveness gaps: a new concept for evaluating health service and research needs applied to complementary and alternative medicine. J Altern Complement Med 2004; 10:627–632.
   PubMed Web of Science ®Google Scholar
• Pittler M, Abbot N, Harkness E, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 2000; 53:485–489.
   PubMed Web of Science ®Google Scholar
• Linde K, Berner M, Kriston L. St John's wort for major depression. Cochrane Database of Systematic Reviews 2008; 4: CD000448.
   PubMed Web of Science ®Google Scholar
• Pittler M, Abbot N, Harkness E, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiology 2000; 53:485–489.
   PubMed Web of Science ®Google Scholar
• Brevoort P. The blooming U.S. botanical market: a new overview. Herbalgram 1998; 44:33–46.
   Google Scholar
• Carpenter C, Crigger N, Kugler R, Loya A. Hypericum and nurses: a comprehensive literature review on the efficacy of St. John's Wort in the treatment of depression. J Holist Nurs 2008; 26:200–207; discussion 208–211.
   PubMedGoogle Scholar
• Ni H, Simile C, Hardy A. Utilization of complementary and alternative medicine by United States adults: results from the 1999 National Health Interview Survey. Med Care 2002; 40:353–358.
   PubMed Web of Science ®Google Scholar
• Linde K. St. John's wort: an overview. Forsch Komplementarmed 2009; 16:146–155.
   Google Scholar
• Butterweck V. Mechanism of action of St. John's wort in depression: what is known? CNS Drugs 2003; 17:539–562.
   PubMed Web of Science ®Google Scholar
• Zanoli P. Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Rev 2004; 10:203–218.
   PubMedGoogle Scholar
• Hammerness P, Basch E, Ulbricht C . St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003; 44:271–282.
   PubMed Web of Science ®Google Scholar
• Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression: an overview and meta-analysis of randomised clinical trials. Br Med J 1996; 313:253–258.
   PubMed Web of Science ®Google Scholar
• Gaster B, Holroyd J. St John's wort for depression: a systematic review. Arch Intern Med 2000; 160:152–156.
   PubMed Web of Science ®Google Scholar
• Whiskey E, Wernecke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001; 16:239–252.
   PubMed Web of Science ®Google Scholar
• Lawvere S, Mahoney M. St John's wort. Am Fam Physician 2005; 72:2249–2254.
   PubMed Web of Science ®Google Scholar
• Clement K, Covertson C, Johnson M, Dearing K. St John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006; 20:197–203.
   PubMedGoogle Scholar
• Shelton R, Keller M, Gelenberg A . Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978–1986.
   PubMed Web of Science ®Google Scholar
• Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Psychopharmacology 2006; 39:66–75.
   Google Scholar
• Fava M, Alpert J, Nierenberg A . A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25:441–447.
   PubMed Web of Science ®Google Scholar
• Behnke K, Jensen G, Graubaum H, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002; 19:43–52.
   PubMed Web of Science ®Google Scholar
• van Gurp G, Meterissian G, Haiek L, McCusker J, Bellavance F. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002; 48:905–912.
   PubMed Web of Science ®Google Scholar
• Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 15:61–68.
   PubMed Web of Science ®Google Scholar
• Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999; 49:289–296.
   PubMed Web of Science ®Google Scholar
• Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 2000; 22:411–419.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:118–127.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults. National Clinical Practice Guideline 90 London: National Institute for Health and Clinical Excellence 2009:1–585.
   Google Scholar
• Philipp M, Kohnen R, Hiller K. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 1999; 319:1534–1539.
   PubMed Web of Science ®Google Scholar
• Thornett A. Use of Hypericum as antidepressant. Valid measure of antidepressant efficacy in primary care is needed. Br Med J 2000; 320:1141.
   PubMed Web of Science ®Google Scholar
• Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomised controlled trial. JAMA 2002; 287:1807–1814.
   PubMed Web of Science ®Google Scholar
• Anghelescu I, Kohnen R, Szegedi A, Klement S, Kieser M. Comparison of Hypericum extract WS5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomised multicenter study. Pharmacopsychiatry 2006; 39:213–219.
   PubMed Web of Science ®Google Scholar
• Gastpar M, Singer A, Zeller K. Efficacy and tolerability of Hypericum extract STW3 in long term treatment with a once daily dosage in comparison with sertraline. Pharmacopsychiatry 2005; 38:78–87.
   PubMed Web of Science ®Google Scholar
• Brattstrom A. Long-term effects of St. John's wort (Hypericum perforatum) treatment: A 1-year safety study in mild to moderate depression. Phytomedicine 2009; 16:277–283.
   PubMed Web of Science ®Google Scholar
• Gelenberg A, Shelton R, Crits-Christoph P . The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry 2004; 65:1114–1119.
   PubMed Web of Science ®Google Scholar
• Kasper S, Volz HP, Moller HJ, Dienel A, Kieser M. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression – A double-blind, randomized, placebo controlled long-term trial. Eur Neuropsychopharmacol. 2008; 18: 803–813.
   PubMed Web of Science ®Google Scholar
• Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res 2007; 21:703–716.
   PubMed Web of Science ®Google Scholar
• Whitten D, Myers S, Hawrelak J, Wohlmuth H. The effects of St John's wort extracts on Cy3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006; 62:512–526.
   PubMed Web of Science ®Google Scholar
• Sarris J, Kavanagh D, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2009; 44:32–41.
   PubMed Web of Science ®Google Scholar
• Knuppel L, Linde K. Adverse effects of St. John's wort: a systematic review. J Clin Psychiatry 2004; 65:1470–1479.
   PubMed Web of Science ®Google Scholar
• Finfgeld D. Serotonin syndrome and the use of SSRIs. J Psychosoc Nurs Ment Health Serv 2004; 42:16–20.
   PubMedGoogle Scholar
• Izzo A, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69:1777–1798.
   PubMed Web of Science ®Google Scholar
• Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 2006; 62:225–233.
   PubMed Web of Science ®Google Scholar
• Zhou S. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9:310–322.
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence. Depression: management of depression in primary and secondary care. NICE Clinical Guideline No. 23. London: National Institutes of Health, 2004.
   Google Scholar
• Hughes D, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10:601–615.
   PubMed Web of Science ®Google Scholar
• Burke M, Silkey B, Preskorn S. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry 1994; 55SA:42–52.
   Google Scholar
• Thompson D, Buesching D, Gregor K, Oster G. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care 1996; 2:1239–1246.
   Google Scholar
• Sheehan D, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation. J Clin Psychopharmacol 2004; 24:544–548.
   PubMed Web of Science ®Google Scholar
• Cantrell C, Eaddy M, Shah M, Regan T, Sokol M. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006; 44:300–303.
   PubMed Web of Science ®Google Scholar
• Johnson D. Non-compliance with antidepressant therapy: an underestimated problem. Intern Med 1986; 11:14–17.
   Google Scholar
• Johnson D. Depression: treatment compliance in general practice. Acta Psychiatr Scandinav 1981; 63:968–972.
   Web of Science ®Google Scholar
• Frazer A. Antidepressants. J Clin Psychiatry 1997; 58:9–25.
   PubMed Web of Science ®Google Scholar
• Nierenberg A, Wright E. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999; 60: 7–11.
   PubMed Web of Science ®Google Scholar
• Rascati K, Godley P, Pham H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. J Manag Care Pharm 2001; 7:402–406.
   Google Scholar
• Kim H, Strelzer J, Goebert D. St John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187:532–539.
   PubMed Web of Science ®Google Scholar
• Linde K, Knüppel L. Large-scale observational studies of Hypericum extracts in patients with depressive disorders: a systematic review. Phytomedicine 2005; 12:148–157.
   PubMed Web of Science ®Google Scholar
• Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001; 8: 152–160.
   PubMed Web of Science ®Google Scholar
• Woelke H, Burkhard G, Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug-monitoring study with 3 250 patients. J Geriatr Psychiatry Neurol 1994; 7S1:34–38.
   Google Scholar
• Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo- controlled study. Hum Psychopharmacol 1998; 13:163–169.
   Web of Science ®Google Scholar
• Vorbach E, Hubner W, Arnoldt K. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994; 7S1:S19–23.
   Google Scholar
• Harrer G, Hubner W, Podzuweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: a multicenter double blind study. J Geriatr Psychiatry Neurol 1994; 7S1:S24–28.
   Google Scholar
• Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients: a controlled 6-week clinical trial. Pharmacopsychiatry 1997; 30S2:77–80.
   Google Scholar
• Vorbach E, Arnoldt K, Hubner W. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Psychopharmacology 1997; 30S2:81–85.
   Google Scholar
• Brockmoller J, Reum T, Bauer S, Kerb R. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30S2:94–101.
   Google Scholar
• Schulz V. Safety of St John's wort extract compared to synthetic antidepressants. Phytomedicine 2006; 13:199–204.
   PubMed Web of Science ®Google Scholar
• Gupta R, Moller H. St John's wort: an option for the primary care treatment of depressive patients? European Archives of Clinical Neuroscience 2003; 253:140–148.
   PubMed Web of Science ®Google Scholar
• Hoencamp E, Stevens A, Haffmans J. Patients’ attitudes towards antidepressants. Psychiatr Serv 2002; 53:1180–1181.
   PubMed Web of Science ®Google Scholar
• Loh A, Leonhart R, Wills C, Simon D, Harter M. The impact of patient participation on adherence and clinical outcome in primary care of depression. Patient Educ Couns 2007; 65:69–78.
   PubMed Web of Science ®Google Scholar
• Dijkstra A, Jaspers M. Psychiatric and psychological factors in patient decision making concerning antidepressant use. J Consult Clin Psychol 2008; 76:149–157.
   PubMed Web of Science ®Google Scholar
• van Schaik D, Klijn A, Van Hout H . Patients preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry 2003; 26:184–189.
   Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Australia's Health 2008. Canberra: Australian Institute of Health and Welfare, 2008.
   Google Scholar
• Lam R, Kennedy S, Grigoriadis S . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117S:26–43.
   Google Scholar
• Taylor C, Chang V. Issues in the dissemination of cognitive behavior therapy. Nordic Journal of Psychiatry 2008; 62S47:37–44.
   Google Scholar
• Heuzenroeder L, Donnelly M, Haby M . Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004; 38:602–612.
   PubMed Web of Science ®Google Scholar
• Vos T, Corry J, Haby M . Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. Aust N Z J Psychiatry 2005; 39:683–692.
   PubMed Web of Science ®Google Scholar
• Gerhards S, de Graaf L, Jacobs L . Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry 2010; 196:310–318.
   PubMed Web of Science ®Google Scholar
• McCrone P, Knapp M, Proudfoot J . Cost-effectiveness of computerised cognitive–behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004; 185:55–62.
   PubMed Web of Science ®Google Scholar
• de Graaf LE, Gerhards SAH, Arntz A . Clinical effectiveness of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry 2009; 195:73–80.
   PubMed Web of Science ®Google Scholar
• van Straten A, Seekles W, van't Veer-Tazelaar N, Beekman A, Cuijpers P. Stepped care for depression in primary care: what should be offered and how? Med J Aust 2010; 192S: 36–39.
   Google Scholar
• Castle D, Schweitzer I, Tiller J. STAR*D: has it taught us anything about the management of depression? Australas Psychiatry 2009; 17:360–364.
   PubMed Web of Science ®Google Scholar